Agentix Corp. Reports $144K Net Loss in Q2 FY 2025, Seeks Additional Funding

Agentix Corp. reported its financial results for the second quarter of fiscal year 2025, revealing a net loss of $144,107 for the three months ended September 30, 2025, compared to a loss of $90,669 during the same period in the previous year. For the six months ending September 30, 2025, the company recorded a net loss of $329,931, up from $241,386 in the prior year. Total operating expenses for the quarter increased to $123,097, a 32% rise from $93,010 in the same quarter of 2024, primarily driven by higher professional fees and research and development costs.

The company’s financial position showed significant changes compared to the previous fiscal period. As of September 30, 2025, Agentix reported total current assets of $5,601, a sharp decline from $100,274 as of March 31, 2025. Current liabilities increased to $3,423,639 from $3,204,523, leading to a total stockholders' deficit of $3,418,038, compared to $3,104,249 in the prior period. The accumulated deficit also widened to $6,851,459 from $6,521,528, indicating ongoing financial challenges.

In terms of strategic developments, Agentix Corp. continues to focus on its core mission of developing therapeutic agents for metabolic diseases, including Type 2 diabetes and obesity. The company has not reported any recent acquisitions or significant product launches in this quarter. However, it has indicated a need for additional funding to support its operations and business plan, as its current cash position is insufficient for daily operations. The company’s cash on hand as of the end of the reporting period was $5,601.

Operationally, Agentix has not disclosed specific customer counts or user statistics in this filing. However, the company has emphasized the importance of generating sufficient revenue and expanding its market presence. The filing indicates that the company is actively pursuing its business plan, which may include geographic expansion and increased product adoption rates, although specific metrics were not provided. The company’s employee headcount remains stable at 40,066,951 shares outstanding, unchanged from the previous reporting period.

Looking ahead, Agentix Corp. has expressed cautious optimism regarding its future operations, contingent upon its ability to secure additional financing and successfully implement its business strategies. The company acknowledges the potential impact of market conditions and competition on its performance, and it has cautioned investors about the inherent uncertainties in its forward-looking statements. The management remains focused on overcoming current financial challenges while striving to achieve its long-term objectives in the biotechnology sector.